For these reasons, mutant KRAS has become a predictor of resistance to EGFR-mAbs and has allowed for the implementation of personalized medicine in CRC patients according to their genotype (KRAS-wild or mutated) [33,147]. This evidence concerns the gene KRAS and colorectal carcinoma.